Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence
Obesity · 2023-05 · 31 (5) · 1280-1289
DOI: 10.1002/oby.23736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obesity, online erschienen am 30.03.2023. Verfasst von Natia Murvelashvili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Bariatric Surgery, Liraglutide, Obesity, Morbid, Weight Gain. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Objective
The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery (MBS) weight recurrence.
Methods
A retrospective analysis of 207 adults with post‐MBS weight recurrence treated with semaglutide 1.0 mg weekly ( n = 115) or liraglutide 3.0 mg daily ( n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide.
Results
The mean sample age was 55.2 years; mean BMI was 40.4 kg/m 2 ; 89.9% were female; and 50% completed sleeve gastrectomy, 29% completed Roux‐en‐Y gastric bypass, and 21% completed adjustable gastric banding. Least‐squares mean weight change at 12 months was −12.92% versus −8.77% in the semaglutide and liraglutide groups, respectively ( p < 0.001). The adjusted odds ratios were 2.34 (95% CI: 1.28‐4.29) for ≥10% weight loss and 2.55 (95% CI: 1.22‐5.36) for ≥15% weight loss over 12 months in the semaglutide group versus liraglutide group, respectively. Weight‐loss efficacy of semaglutide (vs. liraglutide) did not differ by subgroups explored, including age, sex, and MBS procedure.
Conclusions
These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post‐MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
- University of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.
- Center for Pediatric Population Health, UT Health School of Public Health, Dallas, Texas, USA.
- Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics, John P. and Kathrine G. McGovern School of Medicine at UTHealth, Houston, Texas, USA.
ORCID-Profile: Luyu Xie, Ildiko Lingvay, Sarah E Messiah, Jaime P Almandoz
Förderung
- NIDDK NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Murvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023). Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity, 31(5), 1280-1289. https://doi.org/10.1002/oby.23736
Vancouver
Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280-1289. doi:10.1002/oby.23736
BibTeX
@article{Murvelashvili2023,
author = {Murvelashvili, Natia and Xie, Luyu and Schellinger, Jeffrey N and Mathew, M Sunil and Marroquin, Elisa Morales and Lingvay, Ildiko and Messiah, Sarah E and Almandoz, Jaime P},
title = {Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence},
journal = {Obesity},
year = {2023},
volume = {31},
number = {5},
pages = {1280--1289},
doi = {10.1002/oby.23736}
}
EUVIMED